Research Output per year
Fingerprint Dive into the research topics where Jorge Eduardo Cortes is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 3 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects
THERAPY OF CML
Cortes, J. E., Kurzrock, R., Ming-Sheng, L., Reading, C., Emerson, S., Liang, J., Deisseroth, A., Feinberg, A., Siciliano, M., Kantarjian, H., Talpaz, M., Andreeff, M., Kornblau, S., Thall, P., Issa, J. P., Estrov, Z., Arlinghaus, R. B., Deininger, M., Champlin, R., Shpall, E., Austin, D., Claxton, D., Belmont, J., Reisner, Y. & Issa, K.
Project: Research project
Research Output
A heavy metal baseline score predicts outcome in acute myeloid leukemia
Ohanian, M., Telouk, P., Kornblau, S., Albarede, F., Ruvolo, P., Tidwell, R. S. S., Plesa, A., Kanagal-Shamanna, R., Matera, E. L., Cortes, J., Carson, A. & Dumontet, C., 2020, (Accepted/In press) In : American Journal of Hematology.Research output: Contribution to journal › Article
Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype
Samra, B., Richard-Carpentier, G., Kadia, T. M., Ravandi, F., Daver, N., DiNardo, C. D., Issa, G. C., Bose, P., Konopleva, M. Y., Yilmaz, M., Ohanian, M., Borthakur, G., Garcia-Manero, G., Pierce, S., Cortes, J. E., Kantarjian, H. & Short, N. J., May 1 2020, In : Blood Cancer Journal. 10, 5, 47.Research output: Contribution to journal › Article
Open Access
Clinical value of event-free survival in acute myeloid leukemia
Maiti, A., Kantarjian, H. M., Popat, V., Borthakur, G., Garcia-Manero, G., Konopleva, M. Y., DiNardo, C. D., Verstovsek, S., Andreeff, M., Kadia, T. M., Ajufo, H. O., Goswamy, R. V., Blanco, C., Velasquez, M., Daver, N. G., Pemmaraju, N., Pierce, S. R., Wierda, W. G., Kornblau, S. M., Ravandi, F. & 1 others, , Apr 28 2020, In : Blood Advances. 4, 8, p. 1690-1699 10 p.Research output: Contribution to journal › Article
Open Access
Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia
Kolitz, J. E., Strickland, S. A., Cortes, J. E., Hogge, D., Lancet, J. E., Goldberg, S. L., Villa, K. F., Ryan, R. J., Chiarella, M., Louie, A. C., Ritchie, E. K. & Stuart, R. K., Feb 23 2020, In : Leukemia and Lymphoma. 61, 3, p. 631-640 10 p.Research output: Contribution to journal › Article
Open Access
1
Scopus
citations
Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
Cortes, J. E., Jiang, Q., Wang, J., Weng, J., Zhu, H., Liu, X., Hochhaus, A., Kim, D. W., Radich, J., Savona, M., Martin-Regueira, P., Sy, O., Gurnani, R. & Saglio, G., Aug 1 2020, In : Leukemia. 34, 8, p. 2064-2073 10 p.Research output: Contribution to journal › Article
Open Access